Prosecution Insights
Last updated: May 29, 2026

National Health Research Institutes

4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days

Portfolio Summary

4
Total Pending OAs
2
Non-Final OAs
1
Final Rejections
1
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

2
Overdue
0
Due this week
0
Due this month
2
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (2)Due ≤ 60 days (2)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
2
Medium (50%)
0
Easy (0%)
2
Unknown (50%)

Rejection Statute Mix

BucketCases
§103 only2 (50%)
No statute on record2 (50%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

4
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

40 h
Manual time on pending OAs
8 h
Time saved (low, 20%)
14 h
Time saved (mid, 35%)
0.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
VALLE, ERNESTO 1 60.0% +33.3%
HECK, BRYAN WILLIAM 1 46.9% +70.3%
CORNELIUS, CLAIRE ADRIENNE 1
PLAYER, ROBERT AUSTIN 1 16.7% +90.9%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
17749164 CONSTRUCTION METHOD OF RIBOSOMAL RNA DATABASE PLAYER, ROBERT AUSTIN 36d

Interview Candidates (3)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
18476345 PHARMACEUTICAL COMPOSITION COMPRISING TOLL-LIKE RECEPTOR AGONIST AND STIMULATOR OF INTERFERON GENES AGONIST AND USE THEREOF HECK, BRYAN WILLIAM 26d overdue
18374326 INHIBITORS OF POSITIVE STRAND RNA VIRUSES VALLE, ERNESTO 34d
17749164 CONSTRUCTION METHOD OF RIBOSOMAL RNA DATABASE PLAYER, ROBERT AUSTIN 36d

Top Art Units

Art UnitApps
1623 1
1643 1
1672 1
1686 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18374326 INHIBITORS OF POSITIVE STRAND RNA VIRUSES VALLE, ERNESTO 1623 Other Non-Final OA 34d Pending Sep 28, 2023
18476345 PHARMACEUTICAL COMPOSITION COMPRISING TOLL-LIKE RECEPTOR AGONIST AND STIMULATOR OF INTERFERON GENES AGONIST AND USE THEREOF HECK, BRYAN WILLIAM 1643 Other Non-Final OA 26d overdue Pending Sep 28, 2023
18229010 LIPIDATED FLIPR AND USES THEREOF IN VACCINE CORNELIUS, CLAIRE ADRIENNE 1672 §103 Non-Final OA 99d overdue Pending Aug 01, 2023
17749164 CONSTRUCTION METHOD OF RIBOSOMAL RNA DATABASE PLAYER, ROBERT AUSTIN 1686 §103 Final Rejection 36d Pending May 20, 2022

Managing National Health Research Institutes's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month